Optimised compounds

Inventors: David Jackson (Melbourne, AU); Ian Holmes (Melbourne, AU); Weiguang Zeng (Melbourne, AU); Christophe Demaison (Melbourne, AU)

Assignee: AXELIA ONCOLOGY PTY LTD

C07K5/0606 A61K47/542 A61K47/60 A61P11/00 C07C317/48 C07C323/60 A61K38/00

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,157,777
App. No.: 16/768,341
Granted: Dec 3, 2024
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present invention relates to TLR2 agonist compounds and their compositions, and the use of such compounds and compositions in the prevention and/or treatment of respiratory infections, or diseases or conditions associated with viral or bacterial infections.

Claims (10)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. A compound:

or a pharmaceutically acceptable salt thereof.

5. A compound:

or a pharmaceutically acceptable salt thereof.

Assignments (7)

CHANGE OF NAME Recorded Apr 11, 2023

From: INNAVAC PTY LTD

To: ENA THERAPEUTICS PTY LTD

Reel/Frame 063295/0371 →

CHANGE OF NAME Recorded Apr 11, 2023

From: ENA THERAPEUTICS PTY LTD

To: AXELIA ONCOLOGY PTY LTD

Reel/Frame 063295/0373 →